Honest Co. shares surge on positive revenue outlook
By Stephen Nakrosis
Honest Co. shares (HNST) were trading in the green after hours following the release of fourth-quarter financial results that showed revenue increasing and the company swinging to a gain.
After the bell, the company's stock rose 29%, above previous 52-week highs, to trade at $4.06 per share. The stock touched a 52-week high of $3.65 on Feb. 26. Shares ended Wednesday's regular session with a 5.35% gain, closing at $3.15 each.
After the bell, the personal-care company reported fourth-quarter earnings per share of one cent on revenue of $90.3 million. In the year-ago period, the company reported a loss per share of 14 cents on revenue of $81.9 million.
Honest said it was expecting full fiscal-year 2024 net revenue growth of low- to mid-single-digit percentage. "Beyond 2024, the company expects to realize revenue growth of 4% to 6% annually and continued adjusted Ebitda margin expansion," it said.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-06-24 1828ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks